Neuropathic corneal pain treatment filed with FDA
OKYO Pharma, a clinical-stage biopharmaceutical company developing therapies for the treatment of neuropathic corneal pain and inflammatory dry eye disease has filed an application for Fast Track designation with the US Food and Drug Administration (FDA) for urcosimod (formerly known as OK-101). The company intends to use urcosimod for the… Read More